US actor and climate activist Leonardo DiCaprio has taken an investment in two different lab-grown meat startups, the companies announced Wednesday.

DiCaprio has bought an unspecified stake in Aleph Farms and Mosa Meat, two companies developing protein products grown from cow cells -- an emerging area in the growing alternative meat market.

The Academy Award-winning actor will also act as an advisor to the companies, said a joint press release from Israel-based Aleph Farms and Netherlands-based Mosa Meat.

"One of the most impactful ways to combat the climate crisis is to transform our food system," DiCaprio said in the news release. "Mosa Meat and Aleph Farms offer new ways to satisfy the world's demand for beef, while solving some of the most pressing issues of current industrial beef production."

Actor Leonardo DiCaprio, shown here at a 2017 climate change march in Washington, has taken stakes in two alternative meat companies
Actor Leonardo DiCaprio, shown here at a 2017 climate change march in Washington, has taken stakes in two alternative meat companies AFP / Jose Luis Magana

The announcement comes on the heels of earlier investments by the "Titanic" star in publicly traded Beyond Meat, which sells burgers and sausages made from plants.

Aleph Farms "grows beef steaks, from non-genetically engineered cells isolated from a living cow, without harming animals and with a significantly reduced impact to the environment," while Mosa Meat "introduced the world's first cultivated beef hamburger in 2013, by growing it directly from cow cells," according to the press release.

Alternative meat advocates characterize such ventures as a critical component of addressing climate change.

Conventional livestock management is a source of greenhouse gases through the clearing of trees to make room for animal feed production and the raising of livestock, and emissions from the animals themselves.

But while plant-based meat has made its way to mainstream supermarkets, cultivated meat remains at a much earlier stage of commercialization. Costs remain high, and thus far only Singapore has approved the sale of such products.